Karyopharm Reports Positive Phase 3 Data For Selinexor Combo In Myelofibrosis; Stock Up

Karyopharm Therapeutics Inc. (KPTI) on Tuesday reported positive topline results from its Phase 3 SENTRY trial of selinexor in combination with ruxolitinib in frontline myelofibrosis. Karyopharm shares were up more than 15% in pre-market trading.The trial met its first co-primary endpoint, showing a statistically significant improvement in spleen volume reduction of at least 35% (SVR35) in patients treated with the combination compared with ruxolitinib alone.At week 24, 50% of patients receiving the seline ...